- Home
- RBOT vs NCEL Comparison
RBOT vs NCEL Comparison
Compare RBOT & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | NCEL |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 20.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | NCEL |
|---|---|---|
| Price | $2.59 | $2.23 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 146.2K | 121.4K |
| Earning Date | 11-12-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.89 |
| 52 Week High | $18.75 | $7.64 |
Technical Indicators
Market Signals| Indicator | RBOT | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | N/A |
| Support Level | $2.40 | N/A |
| Resistance Level | $2.76 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 80.00 | 0.00 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.